Losartan with add-on spironolactone for severe COVID-19 in the intensive care unit: a randomized controlled trial

Simeone et al., Respiratory Medicine, doi:10.1016/j.rmed.2026.109175, NCT04643691, Sep 2026
Late treatmentRCT · 74 patients · France · Sep 2020 – Sep 2021
Losartan for COVID-19
Lower mortality and ventilation
Not statistically significant · p = 0.45 (mortality) and p = 0.3 (ventilation)
RCT 74 ICU patients (modified intention-to-treat) showing no significant differences with losartan plus conditional add-on spironolactone for severe COVID-19 ARDS.
risk of death, 37.0% lower, HR 0.63, p = 0.45, treatment 4 of 35 (11.4%), control 7 of 39 (17.9%), NNT 15, Cox proportional hazards, day 90.
risk of death, 36.0% lower, RR 0.64, p = 0.40, treatment 4 of 35 (11.4%), control 7 of 39 (17.9%), NNT 15, day 90.
risk of mechanical ventilation, 27.0% lower, RR 0.73, p = 0.30, treatment 11 of 32 (34.4%), control 17 of 36 (47.2%), NNT 7.8, intubation, excludes patients already on invasive MV at inclusion.
oxygen time, 36.8% lower, relative time 0.63, p = 0.30, treatment median 12.0 IQR 19.0 n=32, control median 19.0 IQR 17.0 n=36, oxygen therapy duration (days).
oxygen time, no change, relative time 1.00, p = 1.00, treatment median 6.0 IQR 3.0 n=32, control median 6.0 IQR 5.0 n=36, NHFO duration (days).
SOFA score, 33.3% lower, RR 0.67, p = 0.50, treatment median 2.0 IQR 3.0 n=34, control median 3.0 IQR 2.0 n=39, day 7, primary outcome.
risk of viral load, 3.7% lower, RR 0.96, p = 0.34, treatment median 30.1 IQR 8.2 n=35, control median 29.0 IQR 4.8 n=39, relative Ct values, Supp. Fig 1, day 7.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Simeone et al., 25 Sep 2026, Randomized Controlled Trial, France, peer-reviewed, 41 authors, study period September 2020 - September 2021, trial NCT04643691 (history). Contact: pierre.simeone@ap-hm.fr.
$0 $500 $1,000+ Efficacy vs. cost for COVID-19 treatment protocols c19early.org October 2026 France Angola Colombia Kenya Mozambique Myanmar South Africa Peru Philippines Vietnam Japan Argentina Nepal Iran Bangladesh Ethiopia Ghana Germany Mexico South Korea United Kingdom Saudi Arabia Algeria Morocco Yemen Poland Uzbekistan India China Venezuela DR Congo Madagascar Thailand Uganda Egypt Nigeria Taiwan Fiji Zambia Bosnia-Herzegovina Jordan Georgia Switzerland Dominican Republic Bolivia Côte d'Ivoire Eritrea Togo Bulgaria Greece Slovakia Iceland New Zealand Trinidad and Tobago Mongolia Czechia Belarus Israel Haiti North Macedonia Hong Kong Qatar Panama Serbia France favored high-profit treatments.The average efficacy of treatments was very low.High-cost protocols reduce early treatment, andforgo complementary/synergistic benefits. More effective More expensive 75% 50% 25% ≤0%
$0 $500 $1,000+ Efficacy vs. cost for COVID-19treatment protocols worldwide c19early.org October 2026 France Angola Colombia Kenya Mozambique Myanmar South Africa Peru Philippines Vietnam Japan Argentina Nepal Iran Bangladesh Ethiopia Ghana Germany Mexico South Korea United Kingdom Saudi Arabia Algeria Morocco Yemen Poland Uzbekistan India China Venezuela DR Congo Madagascar Thailand Uganda Egypt Taiwan Fiji Zambia Jordan Georgia Switzerland Dominican Rep. Bolivia Côte d'Ivoire Eritrea Togo Sri Lanka Bulgaria Greece Slovakia New Zealand Trinidad and Tobago Mongolia Czechia Belarus Israel North Macedonia Hong Kong Qatar Panama Serbia France favored high-profit treatments.The average efficacy was very low.High-cost protocols reduce early treatment,and forgo complementary/synergistic benefits. More effective More expensive 75% 50% 25% ≤0%
Abstract: Original Research Losartan with add-on spironolactone for severe COVID-19 in the intensive care unit: a randomized controlled trial Pierre Simeone a,b,* , Julien Carvelli d , Jeanne Morel a , Imane Inal a , Francois Silhol c , Bernard Vaïsse c , Camille Vaïsse c , V ´ eronique Veit e , Estelle Jean e , Baptiste Andr ´ e e , Benjamin De Sainte Marie e , Laurent Lefebvre f , Romain Ronfl ´ e f , Marc Leone g , Laurent Zieleskiewicz g , Gary Duclos g , Alexandre Lopez g , Salah Boussen a,h , Sophie Cataldi a , Xavier Roche a , Arthur Malet a , Jean-Baptiste Denis a , Alexandre Castelli a , Mehdi Assal a , Timoth ´ ee Morales a , Kevin Cot a , Thibault Pechayre a , Pierre-Henri Legal a , Marie Fleury a , Chlo ´ e Guigal a , Lucas Vizerie a , Howard Max a , David Lagier i , Benoit Guinard i , Romain Gomert i , Thibault Triglia j , Djamel Mokart k , Karine Baumstarck l , Mohamed Boucekine l , Lionel Velly a,b , Nicolas Bruder a a Department of Anaesthesiology and Critical Care Medicine, Aix Marseille University, University Hospital Timone, Marseille, France b CNRS, INT, Inst Neurosci Timone, Aix Marseille University, Marseille, France c Cardiology Department, HTA and Vascular Medicine, Aix Marseille University, University Hospital Timone, Marseille, France d Emergency Intensive Care Unit, Aix Marseille University, University Hospital Timone, Marseille, France e Department of Internal Medicine, Aix Marseille University, University Hospital Timone, Marseille, France f Department of Critical Care Medicine, Aix-en-Provence Hospital, Aix-en-Provence, France - g Department of Anaesthesiology and Critical Care Medicine, Aix Marseille University, University Hospital Nord, Marseille, France h Aix Marseille University, IFSTTAR, Marseille, 13916, France i Department of Anesthesia and Critical Care (SAR1), Aix Marseille University, University Hospital Timone, Marseille, France j Department of Anaesthesiology and Critical Care Medicine, Saint-Joseph Hospital, Marseille, France k Critical Care Department, Institut Paoli Calmettes, Marseille, France l Department of Public Health Aix Marseille University, University Hospital of Marseille, Marseille, France A R T I C L E I N F O Keywords: COVID-19 ARDS Renin -angiotensin system AT1R blocker Losartan A B S T R A C T Background: The Coronavirus disease (COVID-19) pandemic caused significant mortality, predominantly among patients with comorbidities. Management of critically ill patients relies mainly on supportive care. SARS-CoV-2 influences the renin-angiotensin system, a potential therapeutic target. The aim was to evaluate whether losartan and spironolactone, added to standard care, improve organ failure and other clinical outcomes in patients with severe COVID-19 admitted to intensive care units. We designed a randomized, open-label, parallel-group trial, in five intensive care units in Marseille, France, from September 2020 to September 2021. Methods: Adults with COVID-19-related respiratory distress were randomized. The experimental group received standard care plus losartan and conditional addition of spironolactone for 10 days while the control group received standard care alone. The primary endpoint was the SOFA-score on day 7. Secondary endpoints included SOFA scores at other time points, intubation rates, mechanical ventilation duration, 90-day mortality, viral replication, and safety. Results: 78 patients were randomized (39 in the control group,..
DOI record: { "DOI": "10.1016/j.rmed.2026.109175", "ISSN": [ "0954-6111" ], "URL": "http://dx.doi.org/10.1016/j.rmed.2026.109175", "alternative-id": [ "S0954611126005445" ], "article-number": "109175", "assertion": [ { "label": "This article is maintained by", "name": "publisher", "value": "Elsevier" }, { "label": "Article Title", "name": "articletitle", "value": "Losartan with add-on spironolactone for severe COVID-19 in the intensive care unit: a randomized controlled trial" }, { "label": "Journal Title", "name": "journaltitle", "value": "Respiratory Medicine" }, { "label": "CrossRef DOI link to publisher maintained version", "name": "articlelink", "value": "https://doi.org/10.1016/j.rmed.2026.109175" }, { "label": "Content Type", "name": "content_type", "value": "article" }, { "label": "Copyright", "name": "copyright", "value": "© 2026 The Authors. Published by Elsevier Ltd." } ], "author": [ { "ORCID": "https://orcid.org/0000-0002-0682-9405", "affiliation": [], "authenticated-orcid": false, "family": "Simeone", "given": "Pierre", "role": [ { "role": "author", "vocabulary": "crossref" } ], "sequence": "first" }, { "ORCID": "https://orcid.org/0000-0003-1305-9805", "affiliation": [], "authenticated-orcid": false, "family": "Carvelli", "given": "Julien", "role": [ { "role": "author", "vocabulary": "crossref" } ], "sequence": "additional" }, { "affiliation": [], "family": "Morel", "given": "Jeanne", "role": [ { "role": "author", "vocabulary": "crossref" } ], "sequence": "additional" }, { "affiliation": [], "family": "Inal", "given": "Imane", "role": [ { "role": "author", "vocabulary": "crossref" } ], "sequence": "additional" }, { "affiliation": [], "family": "Silhol", "given": "Francois", "role": [ { "role": "author", "vocabulary": "crossref" } ], "sequence": "additional" }, { "affiliation": [], "family": "Vaïsse", "given": "Bernard", "role": [ { "role": "author", "vocabulary": "crossref" } ], "sequence": "additional" }, { "affiliation": [], "family": "Vaïsse", "given": "Camille", "role": [ { "role": "author", "vocabulary": "crossref" } ], "sequence": "additional" }, { "affiliation": [], "family": "Veit", "given": "Véronique", "role": [ { "role": "author", "vocabulary": "crossref" } ], "sequence": "additional" }, { "affiliation": [], "family": "Jean", "given": "Estelle", "role": [ { "role": "author", "vocabulary": "crossref" } ], "sequence": "additional" }, { "affiliation": [], "family": "André", "given": "Baptiste", "role": [ { "role": "author", "vocabulary": "crossref" } ], "sequence": "additional" }, { "affiliation": [], "family": "De Sainte Marie", "given": "Benjamin", "role": [ { "role": "author", "vocabulary": "crossref" } ], "sequence": "additional" }, { "affiliation": [], "family": "Lefebvre", "given": "Laurent", "role": [ { "role": "author", "vocabulary": "crossref" } ], "sequence": "additional" }, { "affiliation": [], "family": "Ronflé", "given": "Romain", "role": [ { "role": "author", "vocabulary": "crossref" } ], "sequence": "additional" }, { "affiliation": [], "family": "Leone", "given": "Marc", "role": [ { "role": "author", "vocabulary": "crossref" } ], "sequence": "additional" }, { "affiliation": [], "family": "Zieleskiewicz", "given": "Laurent", "role": [ { "role": "author", "vocabulary": "crossref" } ], "sequence": "additional" }, { "ORCID": "https://orcid.org/0000-0002-3305-0077", "affiliation": [], "authenticated-orcid": false, "family": "Duclos", "given": "Gary", "role": [ { "role": "author", "vocabulary": "crossref" } ], "sequence": "additional" }, { "affiliation": [], "family": "Lopez", "given": "Alexandre", "role": [ { "role": "author", "vocabulary": "crossref" } ], "sequence": "additional" }, { "affiliation": [], "family": "Boussen", "given": "Salah", "role": [ { "role": "author", "vocabulary": "crossref" } ], "sequence": "additional" }, { "affiliation": [], "family": "Cataldi", "given": "Sophie", "role": [ { "role": "author", "vocabulary": "crossref" } ], "sequence": "additional" }, { "affiliation": [], "family": "Roche", "given": "Xavier", "role": [ { "role": "author", "vocabulary": "crossref" } ], "sequence": "additional" }, { "affiliation": [], "family": "Malet", "given": "Arthur", "role": [ { "role": "author", "vocabulary": "crossref" } ], "sequence": "additional" }, { "affiliation": [], "family": "Denis", "given": "Jean-Baptiste", "role": [ { "role": "author", "vocabulary": "crossref" } ], "sequence": "additional" }, { "affiliation": [], "family": "Castelli", "given": "Alexandre", "role": [ { "role": "author", "vocabulary": "crossref" } ], "sequence": "additional" }, { "affiliation": [], "family": "Assal", "given": "Mehdi", "role": [ { "role": "author", "vocabulary": "crossref" } ], "sequence": "additional" }, { "affiliation": [], "family": "Morales", "given": "Timothée", "role": [ { "role": "author", "vocabulary": "crossref" } ], "sequence": "additional" }, { "affiliation": [], "family": "Cot", "given": "Kevin", "role": [ { "role": "author", "vocabulary": "crossref" } ], "sequence": "additional" }, { "affiliation": [], "family": "Pechayre", "given": "Thibault", "role": [ { "role": "author", "vocabulary": "crossref" } ], "sequence": "additional" }, { "affiliation": [], "family": "Legal", "given": "Pierre-Henri", "role": [ { "role": "author", "vocabulary": "crossref" } ], "sequence": "additional" }, { "affiliation": [], "family": "Fleury", "given": "Marie", "role": [ { "role": "author", "vocabulary": "crossref" } ], "sequence": "additional" }, { "affiliation": [], "family": "Guigal", "given": "Chloé", "role": [ { "role": "author", "vocabulary": "crossref" } ], "sequence": "additional" }, { "affiliation": [], "family": "Vizerie", "given": "Lucas", "role": [ { "role": "author", "vocabulary": "crossref" } ], "sequence": "additional" }, { "affiliation": [], "family": "Max", "given": "Howard", "role": [ { "role": "author", "vocabulary": "crossref" } ], "sequence": "additional" }, { "affiliation": [], "family": "Lagier", "given": "David", "role": [ { "role": "author", "vocabulary": "crossref" } ], "sequence": "additional" }, { "affiliation": [], "family": "Guinard", "given": "Benoit", "role": [ { "role": "author", "vocabulary": "crossref" } ], "sequence": "additional" }, { "affiliation": [], "family": "Gomert", "given": "Romain", "role": [ { "role": "author", "vocabulary": "crossref" } ], "sequence": "additional" }, { "affiliation": [], "family": "Triglia", "given": "Thibault", "role": [ { "role": "author", "vocabulary": "crossref" } ], "sequence": "additional" }, { "affiliation": [], "family": "Mokart", "given": "Djamel", "role": [ { "role": "author", "vocabulary": "crossref" } ], "sequence": "additional" }, { "affiliation": [], "family": "Baumstarck", "given": "Karine", "role": [ { "role": "author", "vocabulary": "crossref" } ], "sequence": "additional" }, { "affiliation": [], "family": "Boucekine", "given": "Mohamed", "role": [ { "role": "author", "vocabulary": "crossref" } ], "sequence": "additional" }, { "affiliation": [], "family": "Velly", "given": "Lionel", "role": [ { "role": "author", "vocabulary": "crossref" } ], "sequence": "additional" }, { "affiliation": [], "family": "Bruder", "given": "Nicolas", "role": [ { "role": "author", "vocabulary": "crossref" } ], "sequence": "additional" } ], "container-title": "Respiratory Medicine", "container-title-short": "Respiratory Medicine", "content-domain": { "crossmark-restriction": true, "domain": [ "clinicalkey.com", "clinicalkey.com.au", "clinicalkey.es", "clinicalkey.fr", "clinicalkey.jp", "resmedjournal.com", "elsevier.com", "sciencedirect.com" ] }, "created": { "date-parts": [ [ 2026, 9, 25 ] ], "date-time": "2026-09-25T23:16:38Z", "timestamp": 1790378198000 }, "deposited": { "date-parts": [ [ 2026, 9, 28 ] ], "date-time": "2026-09-28T12:06:02Z", "timestamp": 1790597162000 }, "indexed": { "date-parts": [ [ 2026, 9, 28 ] ], "date-time": "2026-09-28T12:58:31Z", "timestamp": 1790600311337, "version": "4.1.0" }, "is-referenced-by-count": 0, "issued": { "date-parts": [ [ 2026, 11 ] ] }, "language": "en", "license": [ { "URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "content-version": "tdm", "delay-in-days": 0, "start": { "date-parts": [ [ 2026, 11, 1 ] ], "date-time": "2026-11-01T00:00:00Z", "timestamp": 1793491200000 } }, { "URL": "https://www.elsevier.com/legal/tdmrep-license", "content-version": "tdm", "delay-in-days": 0, "start": { "date-parts": [ [ 2026, 11, 1 ] ], "date-time": "2026-11-01T00:00:00Z", "timestamp": 1793491200000 } }, { "URL": "http://creativecommons.org/licenses/by/4.0/", "content-version": "vor", "delay-in-days": 0, "start": { "date-parts": [ [ 2026, 9, 25 ] ], "date-time": "2026-09-25T00:00:00Z", "timestamp": 1790294400000 } } ], "link": [ { "URL": "https://api.elsevier.com/content/article/PII:S0954611126005445?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://api.elsevier.com/content/article/PII:S0954611126005445?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining" } ], "member": "78", "original-title": [], "page": "109175", "prefix": "10.1016", "published": { "date-parts": [ [ 2026, 11 ] ] }, "published-print": { "date-parts": [ [ 2026, 11 ] ] }, "publisher": "Elsevier BV", "reference": [ { "DOI": "10.1001/jama.2020.2648", "article-title": "Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention", "author": "Wu", "doi-asserted-by": "crossref", "first-page": "1239", "issue": "13", "journal-title": "JAMA", "key": "10.1016/j.rmed.2026.109175_bib1", "volume": "323", "year": "2020" }, { "DOI": "10.1016/S0140-6736(20)30566-3", "article-title": "Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study", "author": "Zhou", "doi-asserted-by": "crossref", "first-page": "1054", "journal-title": "Lancet", "key": "10.1016/j.rmed.2026.109175_bib2", "volume": "395", "year": "2020" }, { "DOI": "10.1038/s41586-020-2012-7", "article-title": "A pneumonia outbreak associated with a new coronavirus of probable bat origin", "author": "Zhou", "doi-asserted-by": "crossref", "first-page": "270", "journal-title": "Nature", "key": "10.1016/j.rmed.2026.109175_bib3", "volume": "579", "year": "2020" }, { "DOI": "10.1001/jamainternmed.2020.0994", "article-title": "Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China", "author": "Wu", "doi-asserted-by": "crossref", "first-page": "934", "issue": "7", "journal-title": "JAMA Intern. Med.", "key": "10.1016/j.rmed.2026.109175_bib4", "volume": "180", "year": "2020" }, { "DOI": "10.1056/NEJMoa2001282", "article-title": "A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19", "author": "Cao", "doi-asserted-by": "crossref", "first-page": "1787", "issue": "19", "journal-title": "N. Engl. J. Med.", "key": "10.1016/j.rmed.2026.109175_bib5", "volume": "382", "year": "2020" }, { "DOI": "10.1056/NEJMoa2021436", "article-title": "Dexamethasone in hospitalized patients with Covid-19", "author": "Horby", "doi-asserted-by": "crossref", "first-page": "693", "issue": "8", "journal-title": "N Engl J Med", "key": "10.1016/j.rmed.2026.109175_bib6", "volume": "384", "year": "2021" }, { "DOI": "10.1007/s00134-021-06416-z", "article-title": "Tocilizumab in COVID-19: a meta analysis, trial sequential analysis, and meta-regression of randomized-controlled trials", "author": "Snow", "doi-asserted-by": "crossref", "first-page": "641", "issue": "6", "journal-title": "Intensive Care Med.", "key": "10.1016/j.rmed.2026.109175_bib7", "volume": "47", "year": "2021" }, { "DOI": "10.1056/NEJMoa2007764", "article-title": "Remdesivir for the treatment of Covid-19 - final report", "author": "Beigel", "doi-asserted-by": "crossref", "first-page": "1813", "issue": "19", "journal-title": "N. Engl. J. Med.", "key": "10.1016/j.rmed.2026.109175_bib8", "volume": "383", "year": "2020" }, { "DOI": "10.1097/EJA.0000000000001277", "article-title": "Risk and prognosis of COVID-19 in patients treated with renin-angiotensin-aldosterone inhibitors", "author": "Vistisen", "doi-asserted-by": "crossref", "first-page": "739", "journal-title": "Eur. J. Anaesthesiol.", "key": "10.1016/j.rmed.2026.109175_bib9", "volume": "37", "year": "2020" }, { "article-title": "The endothelium in acute lung injury/acute respiratory distress syndrome", "author": "Maniatis", "first-page": "22", "journal-title": "Curr. Opin. Crit. Care", "key": "10.1016/j.rmed.2026.109175_bib10", "volume": "14", "year": "2008" }, { "DOI": "10.1042/BJ20040634", "article-title": "Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism", "author": "Rice", "doi-asserted-by": "crossref", "first-page": "45", "journal-title": "Biochem. J.", "key": "10.1016/j.rmed.2026.109175_bib11", "volume": "383", "year": "2004" }, { "DOI": "10.1038/nm1267", "article-title": "A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury", "author": "Kuba", "doi-asserted-by": "crossref", "first-page": "875", "journal-title": "Nat. Med.", "key": "10.1016/j.rmed.2026.109175_bib12", "volume": "11", "year": "2005" }, { "DOI": "10.1007/s00134-020-05985-9", "article-title": "Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target", "author": "Zhang", "doi-asserted-by": "crossref", "first-page": "586", "journal-title": "Intensive Care Med.", "key": "10.1016/j.rmed.2026.109175_bib13", "volume": "46", "year": "2020" }, { "DOI": "10.1007/s40264-014-0239-7", "article-title": "The comparative efficacy and safety of the angiotensin receptor blockers in the management of hypertension and other cardiovascular diseases", "author": "Abraham", "doi-asserted-by": "crossref", "first-page": "33", "issue": "1", "journal-title": "Drug Saf.", "key": "10.1016/j.rmed.2026.109175_bib14", "volume": "38", "year": "2015" }, { "DOI": "10.1038/s41440-020-0476-3", "article-title": "Downregulation of ACE2 induces overstimulation of the renin-angiotensin system in COVID-19: should we block the renin-angiotensin system?", "author": "Silhol", "doi-asserted-by": "crossref", "first-page": "854", "issue": "8", "journal-title": "Hypertens. Res.", "key": "10.1016/j.rmed.2026.109175_bib15", "volume": "43", "year": "2020" }, { "key": "10.1016/j.rmed.2026.109175_bib16", "series-title": "Loi N° 2012-300 du 5 mars 2012 relative aux recherches impliquant la personne humaine (1)", "year": "2012" }, { "key": "10.1016/j.rmed.2026.109175_bib17", "series-title": "R: a Language and Environment for Statistical Computing", "year": "2021" }, { "article-title": "COVID-19 and angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: what is the evidence?", "author": "Patel", "first-page": "1769", "issue": "18", "journal-title": "JAMA", "key": "10.1016/j.rmed.2026.109175_bib18", "volume": "323", "year": "2020" }, { "DOI": "10.1002/ddr.21656", "article-title": "Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics", "author": "Gurwitz", "doi-asserted-by": "crossref", "first-page": "537", "issue": "5", "journal-title": "Drug Dev. Res.", "key": "10.1016/j.rmed.2026.109175_bib19", "volume": "81", "year": "2020" }, { "DOI": "10.21037/atm.2016.11.03", "article-title": "Treating the host response to emerging virus diseases: lessons learned from sepsis, pneumonia, influenza and Ebola", "author": "Fedson", "doi-asserted-by": "crossref", "first-page": "421", "issue": "21", "journal-title": "Ann. Transl. Med.", "key": "10.1016/j.rmed.2026.109175_bib20", "volume": "4", "year": "2016" }, { "DOI": "10.1007/s00011-015-0805-1", "article-title": "ACE2 and Ang-(1-7) protect endothelial cell function and prevent early atherosclerosis by inhibiting inflammatory response", "author": "Zhang", "doi-asserted-by": "crossref", "first-page": "253", "issue": "3–4", "journal-title": "Inflamm. Res.", "key": "10.1016/j.rmed.2026.109175_bib21", "volume": "64", "year": "2015" }, { "DOI": "10.1161/01.HYP.0000124667.34652.1a", "article-title": "Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors", "author": "Ishiyama", "doi-asserted-by": "crossref", "first-page": "970", "issue": "5", "journal-title": "Hypertension", "key": "10.1016/j.rmed.2026.109175_bib22", "volume": "43", "year": "2004" }, { "DOI": "10.1111/jcmm.12573", "article-title": "Perinatally administered losartan augments renal ACE2 expression but not cardiac or renal mas receptor in spontaneously hypertensive rats", "author": "Klimas", "doi-asserted-by": "crossref", "first-page": "1965", "journal-title": "J. Cell Mol. Med.", "key": "10.1016/j.rmed.2026.109175_bib23", "volume": "19", "year": "2015" }, { "DOI": "10.1038/srep07027", "article-title": "Angiotensin-converting enzyme 2 (ACE2) mediates influenza H7N9 virus-induced acute lung injury", "author": "Yang", "doi-asserted-by": "crossref", "first-page": "7027", "journal-title": "Sci. Rep.", "key": "10.1016/j.rmed.2026.109175_bib24", "volume": "4", "year": "2014" }, { "DOI": "10.1007/s11427-015-4814-7", "article-title": "Angiotensin II receptor blocker as a novel therapy in acute lung injury induced by avian influenza A H5N1 virus infection in mouse", "author": "Yan", "doi-asserted-by": "crossref", "first-page": "208", "issue": "2", "journal-title": "Sci. China Life Sci.", "key": "10.1016/j.rmed.2026.109175_bib25", "volume": "58", "year": "2015" }, { "DOI": "10.1093/cid/cis733", "article-title": "Population-based study of statins, angiotensin II receptor blockers, and angiotensin-converting enzyme inhibitors on pneumonia-related outcomes", "author": "Mortensen", "doi-asserted-by": "crossref", "first-page": "1466", "issue": "11", "journal-title": "Clin. Infect. Dis.", "key": "10.1016/j.rmed.2026.109175_bib26", "volume": "55", "year": "2012" }, { "DOI": "10.1186/s13054-017-1823-x", "article-title": "A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome", "author": "Khan", "doi-asserted-by": "crossref", "first-page": "234", "issue": "1", "journal-title": "Crit. Care", "key": "10.1016/j.rmed.2026.109175_bib27", "volume": "21", "year": "2017" }, { "DOI": "10.1016/j.eclinm.2021.100957", "article-title": "A multi-center phase II randomized clinical trial of losartan on symptomatic outpatients with COVID-19", "author": "Puskarich", "doi-asserted-by": "crossref", "journal-title": "EClinicalMedicine", "key": "10.1016/j.rmed.2026.109175_bib28", "volume": "37", "year": "2021" }, { "article-title": "Angiotensin receptor blockers for the treatment of covid-19: pragmatic, adaptive, multicentre, phase 3, randomised controlled trial", "author": "Jardine", "journal-title": "Br. Med. J.", "key": "10.1016/j.rmed.2026.109175_bib29", "volume": "379", "year": "2022" }, { "DOI": "10.1038/s41591-021-01410-w", "article-title": "Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom", "author": "Pritchard", "doi-asserted-by": "crossref", "first-page": "1370", "journal-title": "Nat. Med.", "key": "10.1016/j.rmed.2026.109175_bib30", "volume": "27", "year": "2021" }, { "DOI": "10.1128/spectrum.02050-23", "article-title": "Humoral and cellular immune responses against SARS-CoV-2 post-vaccination in immunocompetent and immunocompromised cancer populations", "author": "Titova", "doi-asserted-by": "crossref", "journal-title": "Microbiol. Spectr.", "key": "10.1016/j.rmed.2026.109175_bib31", "volume": "12", "year": "2024" }, { "DOI": "10.1186/s13054-019-2663-7", "article-title": "The SOFA score-development, utility and challenges of accurate assessment in clinical trials", "author": "Lambden", "doi-asserted-by": "crossref", "first-page": "374", "issue": "1", "journal-title": "Crit. Care", "key": "10.1016/j.rmed.2026.109175_bib32", "volume": "23", "year": "2019" }, { "DOI": "10.1186/s13054-022-04290-9", "article-title": "The Sequential Organ Failure Assessment (SOFA) score: has the time come for an update?", "author": "Moreno", "doi-asserted-by": "crossref", "first-page": "15", "issue": "1", "journal-title": "Crit. Care", "key": "10.1016/j.rmed.2026.109175_bib33", "volume": "27", "year": "2023" }, { "DOI": "10.3390/v14112535", "article-title": "ACE2-Independent alternative receptors for SARS-CoV-2", "author": "Lim", "doi-asserted-by": "crossref", "first-page": "2535", "journal-title": "Viruses", "key": "10.1016/j.rmed.2026.109175_bib34", "volume": "14", "year": "2022" }, { "DOI": "10.1016/j.jmii.2020.03.022", "article-title": "Genotype and phenotype of COVID-19: their roles in pathogenesis", "author": "Mousavizadeh", "doi-asserted-by": "crossref", "first-page": "159", "issue": "2", "journal-title": "J. Microbiol. Immunol. Infect.", "key": "10.1016/j.rmed.2026.109175_bib35", "volume": "54", "year": "2021" } ], "reference-count": 35, "references-count": 35, "relation": {}, "resource": { "primary": { "URL": "https://linkinghub.elsevier.com/retrieve/pii/S0954611126005445" } }, "score": 1, "short-title": [], "source": "Crossref", "special_numbering": "C", "subject": [], "subtitle": [], "title": "Losartan with add-on spironolactone for severe COVID-19 in the intensive care unit: a randomized controlled trial", "type": "journal-article", "update-policy": "https://doi.org/10.1016/elsevier_cm_policy", "volume": "263" }
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 200,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.
  or use drag and drop   
Submit